

B1 31 (Amended). A pharmaceutical composition comprising at least one dose of an immunogenically effective amount of a polypeptide of claim [1] ~~37~~ in a pharmacological carrier.

B2 ~~34~~² (Amended). A kit useful for the detection of antibody to the polypeptide of claim [1] ~~37~~¹ in a specimen suspected of containing such antibody, the kit comprising carrier means being compartmentalized to receive in close confinement therein one or more containers comprising a container containing the polypeptide of claim [1] ~~37~~.

B3 ~~37~~¹⁰ (New). A polypeptide consisting of an amino acid sequence having the formula:



wherein n is 1 to about 1000 and Φ is 25 amino acids or less and has the formula:



wherein α and β are independently from 0 to about 5 naturally occurring amino acids, wherein the polypeptide is capable of binding antibody in a specimen from an individual with Epstein-Barr virus (EBV)-associated disease.

38 (New). The polypeptide of Claim 37 wherein Φ is QNSETFTETWNRFITHTEHVD.

~~39~~⁴ (New). The polypeptide of Claim ~~38~~³ wherein n is 1.

B3
Antia
5
40 (New).

The polypeptide of Claim ~~37~~¹ wherein n is 1.

41 (New).

A polypeptide consisting of an amino acid sequence having the formula:

$$\{(\Phi)_n(\Gamma)_o(\Delta)_p(\Omega)_q\}_r$$

wherein:

n is 0-1000,

o is 0-1000,

p is 0-1000,

q is 0-1000,

n + o + p + q = 1-1000,

(n + o + p + q) x r = 1-1000,

Φ is 25 amino acids or less and has the formula (α ETFTETWNRFITHT β),

Γ is 25 amino acids or less and has the formula (α GMLEASEGLDGWIHQ β),

Δ is 25 amino acids or less and has the formula (α HQQGGWSTLIEDNIP β),

Ω is 25 amino acids or less and has the formula (α KQKHPKKVKQAFNPL β),

α and β are each independently from 0 to 5 naturally occurring amino acids, and

the polypeptide is capable of binding antibody in a specimen from an individual

with Epstein-Barr virus (EBV)-associated disease.

*B3
control*
42 (New). A pharmaceutical composition comprising at least one dose of an immunogenically effective amount of a polypeptide of claim 41 in a pharmacological carrier.

7
43 (New). A kit useful for the detection of antibody to the polypeptide capable of binding antibody in a specimen from an individual with Epstein-Barr virus (EBV)-associated disease in a specimen suspected of containing such antibody, the kit comprising carrier means being compartmentalized to receive in close confinement therein one or more containers comprising a container containing the polypeptide of claim ⁶41.

*sub
E3*
44 (New). The polypeptide of claim 41 wherein o is 0 and p is 0.

45 (New). The polypeptide of claim 44 wherein Φ is (QNSETFTETWNRFITHTTEHVD) and Ω is (ARQKQKHPKKVKQAFNPLI).

46 (New). The polypeptide of claim 41 wherein Φ is (QNSETFTETWNRFITHTTEHVD) and Ω is (ARQKQKHPKKVKQAFNPLI).

47 (New). The polypeptide of claim 41 wherein Ω is (ARQKQKHPKKVKQAFNPLI).

DOCKET NO.: ORGU-0023
PATENT APPLICATION

SERIAL NO.: 08/392,934
FILED: OCTOBER 28, 1996

- B3 cancelled with 83*
- 48 (New). The polypeptide of claim 41 wherein n is 0, o is 0 and p is 0.
- 49 (New). The polypeptide of claim 48 wherein q is 1.
- 50 (New). The polypeptide of claim 49 wherein Ω is (ARQKQKHPKKVKQAFNPLI).

B4

IN THE ABSTRACT:

Please add the following abstract after the last page of claims:

Sub P4

--Epstein-Barr virus (EBV) specific polypeptides are disclosed. Also disclosed are the use of these polypeptides for the production of polypeptide-specific antibodies and the diagnosis and treatment of EBV-associated disease.--

REMARKS

Status of the claims

Claims 1-36 are pending in the application.

Claim 2-30, 32, 33 and 35 have been withdrawn from consideration.

Claims 1, 31, 34 and 36 have been rejected.

By way of this amendment, claims 31 and 34 have been amended, claims 1-30, 32, 33, 35 and 36 have been canceled and new claims 37-50 have been added.